BioVie Inc
BIVI
Company Profile
Business description
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Contact
680 W Nye Lane
Suite 204
CarsonNV89703
USAT: +1 775 888-3162
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
14
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 56.70 | 0.65% |
| CAC 40 | 7,738.42 | 75.83 | 0.99% |
| DAX 40 | 23,790.11 | 116.82 | 0.49% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,774.69 | 10.64 | -0.12% |
| HKSE | 24,221.41 | 149.13 | 0.62% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,762.48 | 223.85 | -0.56% |
| NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
| S&P 500 | 6,227.41 | 29.40 | 0.47% |
| S&P/ASX 200 | 8,597.70 | 56.60 | 0.66% |
| SSE Composite Index | 3,454.79 | 2.95 | -0.09% |